INTRODUCTION
3a-Hydroxysteroid dehydrogenase (3a-HSD) catalyses an NAD(P)+-dependent reversible oxidation of 3a-hydroxy group of various steroids and functions in the metabolism of steroid hormones and bile acids. The enzyme activity is distributed in various mammalian tissues, and the cytosolic enzymes purified from liver [1] [2] [3] [4] [5] , prostate [6, 7] , brain [8] and epididymis [9] are monomeric proteins with an Mr of about 35000. Most of the mammalian enzymes transfer hydrogen from the 4-pro-R position of the coenzyme to the substrates [5, 10, 11] , and have been classified as the 'A-specific enzyme' (EC 1.1.1.213) to distinguish it from the 'B-specific enzyme' (EC 1.1.1.50). Since 3a-HSDs of animal livers oxidize trans-dihydrodiols of aromatic hydrocarbons and reduce various exogenous carbonyl compounds [1] [2] [3] [4] [5] , an additional role in xenobiotic metabolism has been suggested for the enzymes. Of the animal 3a-HSDs, the molecular structure of the rat liver enzyme has been studied extensively [12] [13] [14] . The amino acid sequence of rat liver 3a-HSD [12, 13] has a significant sequencing identity with members of the aldo-keto reductase family, which includes prostaglandin F synthase (EC 1.1.1.188) [15] , aldehyde reductase (EC 1.1.1.2) and aldose reductase (EC 1.1.1.21) of mammalian tissues [16, 17] .
Recently, Binstock et al. [18] have isolated a monomeric 3a-HSD from human liver cytosol and reported that the sequences of several peptides from the enzyme are identical with regions of the deduced amino acid sequence of a cDNA for human liver chlordecone reductase (EC 1.1. 1.225) [19] . However, the existence of several chlordecone reductase genes [19] and two proteins immunochemically related to the enzyme in human liver [20] have been reported. In addition, more than two forms of 3a-HSD have been purified from human liver [21, 22] . We previously purified two monomeric dihydrodiol dehydrogenases associated with 3a-HSD activity from human liver [23] and suggested that the C9 and ClI clones encoded DD2 and DD4 respectively, and further indicated that the sequence of DD2 had at least additional 16 residues upward from the N-terminal sequence deduced from the cDNA. There was 82 % amino acid sequence identity between the two enzymes, indicating that the enzymes are genetic isoenzymes. A computer-based comparison of the cDNAs of the isoenzymes with the DNA sequence database revealed that the nucleotide and amino acid sequences of DD2 and DD4 are virtually identical with those of human bile-acid binder and human chlordecone reductase cDNAs respectively. the two enzymes are A-specific 3a-HSD isoenzymes on the basis of their differences in molecular mass, heat-stability and sensitivity to anti-inflammatory agents and bile acid [24] . In the present study, cDNA clones encoding the two human liver 3a-HSDs were isolated to confirm that the two enzymes are genetic isoenzymes and to elucidate their structural relationship with rat 3a-HSD, human liver chlordecone reductase and some other mammalian oxidoreductases.
EXPERIMENTAL Materials
The Agtll human liver cDNA library (HLlO01b #2104) was obtained from Clontech Laboratories; nitrocellulose membranes were from Schleicher and Schuell; poly(vinylidene difluoride) membranes were from Millipore; goat anti-rabbit IgGperoxidase conjugate was from Bio-Rad Laboratories; and bacterial growth media were from Difco. Restriction and DNAmodifying enzymes were purchased from Nippon Gene (Tokyo, Japan) and Takara Shuzou Co. (Kyoto, Japan). The Taq Dye Primer Cycle Sequencing kit and gas-phase-protein-sequencer chemicals were obtained from Applied Biosystems Japan, and a plasmid, pBluescript II SK(+), tor subcloning and sequencing, was from Stratagene. All other chemicals were of the highest grade that could be obtained commercially.
Immunochemical experiments
The two 3a-HSDs, DD2 and DD4, were purified to homogeneity from human liver as previously described [24] . Antibodies against DD2 were raised in rabbits according to the method described by Sawada et al. [25] . The IgG fraction of the antisera was prepared by 0-40 % ammonium sulphate precipitation, and the specificity of the antibodies was analysed by immunoblot analysis [26] . each other, despite their apparent structural and functional difference previously observed [24] . The cross-reactivity allowed us to screen cDNA clones encoding the two enzymes from a human liver cDNA library using the antibodies. A total of 200000 plaques from the cDNA library were screened. In all, 18 immunopositive plaques were obtained, and six clones were isolated. Two had cDNA inserts of about 1.2 kb, and the other four had about 0.8 kb inserts. The two clones, C9 and C 1, containing the largest EcoRI fragments were subjected to sequence determination on both strands, as shown in Figure 2 . The nucleotide and deduced amino acid sequences of C9 and C 11 are shown in Figures 3 and 4 respectively.
The cDNA sequence of C9 contained 1162 bp, of which 920 bp constituted an open reading frame specifying a 306-amino-acid polypeptide followed by 242 bp 3'-untranslated region containing a TAA stop codon, two polyadenylation signallike sequences and a poly(A) track. There was no first ATG codon near the 5'-end of clone C9. The cDNA insert in CII contained 1164 bp with a 965 bp open reading frame, specifying a 321-amino-acid polypeptide, and a 199 bp 3'-untranslated region containing a TAG stop codon, a polyadenylation hexamer and a poly(A) tail. An ATG codon was found at the 5'-end of this mRNA molecule, but the nucleotide context of this AUG (ACUUCAUGC) does not agree with the initiation consensus sequence (CCACCA UGG); specifically, it is very unusual to find a pyrimidine at the third base upstream from an initiator AUG [29] . The other clones, C8, C10, C16 and C18 were sequenced, but their inserts were EcoRI fragments containing bases 1-809 of the sequence of C9 or bases 1-854 of the sequence of ClI ( Figure  2 ).
Amino acid sequences of two 3a-HSDs
No amino acid was found by direct sequencing of the purified DD2 and DD4, suggesting that the N-termini of the enzymes are blocked. When the two proteins were treated with acylaminoacid-releasing enzyme and analysed with a sequencer, a sequence (a) ( of DSKYQCVKLNDGH was yielded from DD2, though no sequence was obtained in the case of DD4. Since the N-terminal sequence of DD2 did not match the deduced amino acid sequences of C9 and ClI, the two enzymes were subjected to digestion by lysyl-endopeptidase or CNBr cleavage and sequences of the peptides purified by h.p.l.c. were determined to confirm that we have cloned the cDNAs for DD2 and DD4.
Two peptides (2A and 2D) were obtained from the CNBr cleavage of DD2 and three peptides (2B, 2C and 2E) were from the lysyl-endopeptidase digestion. The sequence data for the five peptides are shown in Table 1 . Of the peptides, the sequences of 2C, 2D and 2E matched the regions in the deduced amino acid sequence of clone C9 (Figure 3 ), but those of the other two peptides [(2A) DSKYQCVKLNDGHF and (2B) LNDGHJMPVLGFGTYAPAEVPK] were not. However, the sequences of the two peptides were overlapped by the italicised six amino acids, and the peptide 2B contained the same sequence of 14 amino acids as that of the N-terminal portion deduced from the cDNA. In addition, peptide 2A contained the 13-amino-acid N-terminal sequence obtained by digestion with acylamino-acid-releasing enzyme of DD2. This indicates that DD2 has at least an additional sequence of 16 residues upward from the N-terminal amino acid predicted from the cDNA ( Figure 5 ). The Mr of DD2 was calculated to be 36793 from the predicted overall amino acid sequence of 322 residues. This value is compatible with that reported for the purified DD2 (Mr 37 000) [24] . Therefore the sequence of the enzyme in Figure 5 probably lacks only one acylated N-terminal residue of the intact protein.
On the other hand, all the sequences of the six peptides (4A-4F) obtained from the enzymic cleavage of DD4 (Table 2) were identical with regions in the amino acid sequence deduced from clone Cl 1, especially one sequence of the peptide 4A located within a region around the first ATG codon in the deduced amino acid sequence (Figure 4 ). The sequence with 321 amino acids predicted a protein with an Mr of 36847, which is slightly lower than that of the intact DD4 (Mr 39000) previously reported [24] . The result further indicated that the first ATG codon in the cDNA does not initiate translation of the DD4 protein, although the present sequence of DD4 also lacked several N-terminal residues.
Sequence comparison among human liver 30c-HSDs and chlordecone reductase DD2 and DD4 have been thought to be 3a-HSD isoenzymes [24] . The overall amino acid sequences of the two enzymes show 82 % identity ( Figure 5 ). Therefore it is appropriate to conclude that the two enzymes are isoenzymes expressed from separate, but similar, genes. Brinstock et al. [18] have shown that sequences of several peptides obtained from a 3ac-HSD of human liver are identical with regions of the amino acid sequence deduced from a cDNA (CCDR12) for human liver chlordecone reductase, which has been thought to comprise 308 amino acids [19] . When the amino acid sequences of DD2 and DD4 were compared with that of the chlordecone reductase cDNA, the 308-amino-acid Cterminal sequence of DD4 was found to be completely identical with the deduced amino acid sequence of CCDR12. The nucleotide sequences of C 11 and CCDR12 were also identical, except that the C 1 lacks one nucleotide in the 5'-end and has the poly(A)9 compared with the CCDR12 sequence. Thus the isolated cDNA clone encoding DD4, Cl GGA TTT GGC ACC TAT GCG CCT GCA GAG GTT CCT AAA AGT AAA GCT TTA GAG GCC   62  V  L  G  F  G  T  Y  A  P  A  K  V  P  K  S  X  A  L  E  A  20  23   ACC AAA TTG GCA ATT GAA GCT GGC TTC CGC CAT ATT GAT TCT GCT CAT TTA TAC AAT AAT   122  T  K  L  A  I  E  A  G  F  R  B  I  D  S  A  H  L  Y  N  N  40 GAG GAG CAG GTT GGA CTG GCC ATC CGA AGC AAG ATT GCA GAT GGC AGT GTG AAG AGA GAA
GAC ATA TTC TAC ACT TCA AMG CTT TGG TGC AAT TCC CAT CGA CCL GAG TTG GTC CGA CCA 242
GCC TTG GAA AGG TCA CTG AAA AAT CTT CAA TTG GAT TAT GTT GAC CTC TAC CTT ATT CAT
GGA TTG GCC AAG TCC ATC GGG GTG TCC AAC TTC AAC CGC AGG CAG CTG GAG ATG ATC CTC 482
ALC AAG CCA GGG CTC AAG TAC AAG CCT GTC TGC AAC CAG GTG GAA TGT CAT CCT TAC TTC 542
AAC CAG AGA AAA CTG CTG GAT TTC TGC AAG TCA AAA GAC ATT GTT CTG GTT GCC TAT AGT 602
GCT CTG GGA TCC CAC CGA GAA GAA CCA TGG GTG GAC CCG AAC TCC CCG GTG CTC TTG GAG
23 AGA CAG AAC GTG CAG GTG TTT GAL TTC CAG TTG ACT TCA GAG GAG ATG AAA GCC ATA GAT
GGC CTA AAC AGA AAT GTG CGA TAT TTG ACC CTT GAT ATT TTT GCT GGC CCC CCT AAT TAT When the 304-amino-acid C-terminal sequence of DD2 was aligned without amino acid insertions with the deduced amino acid sequence of MDCR2, the identity between the sequences was 97%, with the following eight residue exchanges: amino acids at positions 19, 37, 46, 53, 86, 150, 169 and 171 in the DD2 sequence ( Figure 5) are Pro, Val, His, Val, Ser, Met, His and Leu respectively in the deduced amino acid sequence from MDCR2. Since the residue difference between the two sequences is smaller than those between three subunit types (a, /3 and y) of human liver class-I alcohol dehydrogenase [30] , the translation product ofMDCR2 might be another 3a-HSD isoenzyme. 
ACC TAT GCA CCT CCA GAG GTT CCG AGG AAC AGA GCT GTA GAG GTC ACC AAA TTA GCA ATA
GAA GCT GOC TTC CGC CAT ATT GAT TCT GCT TAT TTA TAC AAT AAT GAG GAG CAG GTT GGA 192
CTG GCC ATC CGA AGC AAG ATT GCA GAT GGC AGT GTG AAG AGA GAL GAC ATA TTC TAC ACT 242 T  80  43  TCA AAG CTT TGG TGC ACT TTC TTT CAA CCA CAG ATG GTC CAA CCA GCC TTG GAA AGC TCA   302  S 
AAG CCA GGT GAG ACG CCA CTA CCk AAA GAT GAA AAT GGA AAA GTA ATA TTC GAC ACA GTG 422
GAT CTC TCT GCC ACA TGG GAG GTC ATG GAG AAG TGT AAG GAT GCA GGA TTG GCC AAG TCC 482
ATC GGG GTG TCA AAC TTC AAC TGC AGG CAG CTG GAG ATG ATC CTC AAC AAG CCA GGA CTC
AAG TAC AAG CCT GTC TGC AAC CAG GTA GAA TOT CAT CCT TAC CTC AAC CAG AGC AAA CTG
CGT GGG GTT GTG GTC CTG GCC AAG AGC TAC AAT GAG CAG CGG ATC AGA GAG AAC ATC CAG 842 The deduced amino acids, stop codon (TAG) and putative polyadenylation signal are shown as in Figure 3 . The first ATG codon is dotted. Bold underlining denotes regions confirmed by protein sequencing of peptides obtained by digestion with lysyl-endopeptidase (4A-4F) of the purified DD4. The peptide sequences (4C and 4E) include some residues (A) that were not identified.
and we previously isolated other monomeric dihydrodiol dehydrogenases associated with 3(20)a-HSD activity, in addition to DD2 and DD4, from a human liver [23] . These findings, together with the present results, suggest that the multiplicity of hepatic 3a-HSD forms is due to the multiplicity and/or polymorphism of 3a-HSD genes, although we cannot exclude the possibility that some forms of 3a-HSD are derived from posttranslational modification of the limited 3a-HSD isoenzymes.
Sequence identity among human liver 3a-HSDs and other proteins A computer-based comparison of the sequence of DD2 with the entries in the NBRF and EMBL databases revealed that its nucleotide sequence was identical with that of the full-length cDNA encoding human liver bile-acid binder [31] , which was recently published as the present paper was being prepared. The present amino acid sequence of DD2 ( Figure 5 ) lacks only the first Met of the deduced sequence from the bile-acid-binder cDNA. The N-terminal sequence analysis of DD2 suggested that the Met of the protein is probably acylated. Bile-acid binder purified from human liver is also a monomeric protein of Mr 36000 that exhibits dihydrodiol dehydrogenase activity [32] . Although the bile-acid binder was reported not to be co-purified with 3a-HSD activity [22, 32] and the recombinant protein is devoid of 3a-HSD activity [31] , bile acids such as lithocholic acid and chenodeoxycholic acid were used as the substrates to detect the 30c-HSD activity in these studies, but 3a-hydroxysteroids such as 3a-hydroxy-5/)-androstan-17-one and 5,/-pregnane- DD2 GLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVS ********************* ***** *** 6******6** 6** Figure 5 Comparison of predicted sequences of D02 and 004
The sequence of DD2 includes the N-terminal portion that was determined only by sequencing of peptides 2A and 2B and is indicated in italics. Asterisks indicate identical amino acid residues between the two sequences. The putative coenzyme-binding and active-site sequences proposed for rat liver 3a-HSD [12, 14] are underlined below the sequence of DD4.
sequences of peptides from the purified human liver bile-acid binder do not match the sequence deduced from the full-length cDNA for this protein [31] , whereas the sequences (84 amino acids in total) of the four peptides (2B-2E) of DD2 were completely identical with the regions in the deduced sequence of clone C9. Further studies will be necessary to clarify the identity of DD2 and bile-acid binder in human liver, although the present clone C9 and the clone for the bile-acid binder are identical cDNAs.
In pairwise alignments, DD2 and DD4 revealed at least 48 % amino acid sequence identity with the aldo-keto reductase family of proteins such as bovine lung prostaglandin F synthase [15], rat liver 3a-HSD [12, 13] and human aldehyde and aldose reductases [16] , as reported with the sequence deduced from cDNAs for human liver chlordecone reductase [18, 19] and bile-acid binder [31] . Of the aldo-keto reductase family of proteins, rat liver 3a-HSD is similar to the two human 3a-HSDs in dual-coenzyme specificity for NADP(H) and NAD(H), specificity for dihydrodiols, alicyclic alcohols and carbonyl compounds, and sensitivity to anti-inflammatory agents [1, 2, 23, 24] . DD2 and DD4 exhibited relatively high sequence identities of about 68 % with rat liver 3a-HSD, and showed conservation of two structural domains that have been found in rat liver 3a-HSD [12] [13] [14] . One is the 'fingerprint' structural motif in the coenzyme-binding sites of many dehydrogenases, GXGXXA (where X is any amino acid) [12, 13, 33, 34] , that is seen between residues 19 and 24 of the sequences of DD4 and DD2 ( Figure 5) . In recent crystallographic studies on the three-dimensional structure of aldose reductase, which has sequence similarity to rat 3a-HSD, the coenzyme-cDNAs of human liver 3a-hydroxysteroid dehydrogenase isoenzymes Table 2 Automated Edman degradation of DD4 peptides generated by lysyl-endopeptidase digestion
The peptides were sequenced, and the phenylthiohydantoin-amino acids released in each cycle were quantified as described in Table 1 binding site exhibits a single domain folded in an eight-stranded parallel /3/a barrel, where 17 residues involved in the NADPH binding have been shown to exist in the middle and C-terminal regions of the enzyme sequence as well as in the N-terminal region [35, 36] . Most of the critical NADPH-binding residues are conserved in the sequences of DD2 and DD4, which suggests that the residues other than the N-terminal residues in the 'fingerprint' motif are also responsible for the coenzyme binding of the human liver 3a-HSDs. Another structural domain common to the human and rat 3a-HSDs is a sequence of SIGVSNFNCR (residues between 161 and 170 in Figure 5 ). The sequence has been identified as an active-site peptide of rat liver 3a-HSD, and the Cys in the sequence has been suggested to be critical to the catalytic function of rat liver 3a-HSD [14] . This Cys is conserved in DD4, whereas it is replaced by Arg in DD2. The broad specificity of DD4 for androgens, pregnanes and bile acids is similar to that of rat liver 3a-HSD, but DD2 catalyses the oxidoreduction of some androgens and pregnanes [24] . The substitution of Cys with Arg might contribute to the difference in steroid specificity between DD2 and DD4. Alternatively, the substitution might be related to the difference in the sensitivity to bile acids between the two human liver enzymes, of which DD2 is potently inhibited [24] . Since the carboxy group at C-24 on free bile-acid molecules, competitive inhibitors with respect to substrate, has been suggested to be important for the binding to DD2 [24] , the electrostatic interaction between the anionic carboxy group of bile acid and the basic amino acid residue might be involved in the binding of inhibitory bile acid to the active site of the enzyme. To clarify the two possibilities, our efforts are currently focused on the structure-function relationship of DD2 by affinity-labelling using bile acid derivatives and by site-directed mutagenesis of the important Arg as the target.
